Survival of Patients with Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small Cell Lung Cancer Treated beyond the Second Line in the Tyrosine Kinase Inhibitor Era

摘要

The identification of activating mutations in specific genes in non-small cell lung cancer (NSCLC) has led to the development of targeted therapies, which are currently part of the algorithm for their management. The recommendations agree on first and second-line metastatic treatments in Epidermal Growth Factor Receptor (EGFR) mutations patients. The aim of our retrospective, longitudinal and analytic study was to analyze the survival of EGFR-mutated patients treated beyond the second line of treatment. We confirmed in a population of 31 patients which received at least three lines of treatment that the Progression Free Survival (PFS) was best if we used chemotherapy in second-line and tyrosine kinase inhibitors (TKI) in third-line. We found no difference in Overall Survival (OS) according to the pattern of treatments. In practice, in the TKI era, chemotherapy can still be used in second-line or third-line of treatment.